CardiacWire
FEBRUARY 12, 2025
Anthos subsequently kicked off three phase 3 trials in 2022, and wrapping up these studies by 2026 will now be Novartis responsibility. Besides the hefty price tag , the re-acquisition puts Novartis back into competition with other big-name Factor XI inhibitor developers, whove faced a series of setbacks.
Dr. Paddy Barrett
DECEMBER 19, 2023
You cannot eliminate the plaque entirely, but multiple clinical trials have shown plaque regression using high-intensity cholesterol-lowering treatments, which I have discussed previously. All of these parameters are important and need to be considered when evaluating plaque regression. REVERSAL Investigators.
Dr. Smith's ECG Blog
SEPTEMBER 18, 2024
Thus, it has recently become generally accepted that most plaque ruptures resulting in myocardial infarction occur in plaques that narrow the lumen diameter by 40% of the arterial cross section may be involved by plaque. The pathologist may see a plaque that constitutes, for example, 50% of the cross-sectional area.
Stroke Journal
FEBRUARY 1, 2024
Background:High-risk non-stenosing carotid plaque features are emerging as a possible source of embolism in the setting of ESUS. We utilized Fisher’s exact test to compare the frequencies of reporting each plaque characteristic.Results:We analyzed 152 CTA reports in depth.
Journal of the American Heart Association
NOVEMBER 28, 2023
BackgroundComplex aortic plaque (CAP) is a potential embolic source in patients with cryptogenic stroke (CS). Most studies (74%) used ≥4 mm plaque thickness as the imaging criterion for CAP although ≥1 mm (N=1, CTA), ≥5 mm (N=5, TEE), and ≥6 mm (N=2, CTA) were also reported. 0.41],I2=94%). I2=95%) for TEE; 0.23 (95% CI, 0.15–0.34;I2=87%)
DAIC
FEBRUARY 3, 2025
Lp(a) is emerging as an important, yet under-recognized, potential risk factor for cardiovascular disease due to its ability to promote the development of plaques within artery walls, clot formation and aortic valve calcification. 2022 Aug, 80 (9) 934946 Kronenberg F.
JAMA Cardiology
MARCH 4, 2025
This is because the test is widely available, fast, highly reproducible, low radiation, directly reflective of total coronary plaque burden, and highly predictive of future atherosclerotic cardiovascular disease (ASCVD) events.
Expert insights. Personalized for you.
102 
Let's personalize your content